<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="50518"><DrugName>aldoxorubicin (cancer), NantCell</DrugName><DrugNamesKey><Name id="42988192">aldoxorubicin</Name><Name id="42990752">aldoxorubicin hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>DOXO-EMCH, University of Freiburg</Value></Name><Name><Value>doxorubicin prodrug, University of Freiburg</Value></Name><Name><Value>doxorubicin (hydrazone derivative), University of Freiburg</Value></Name><Name><Value>aldoxorubicin (cancer), CytRx</Value></Name><Name><Value>tumor-targeted doxorubicin conjugate, CytRx</Value></Name><Name><Value>aldoxorubicin</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>aldoxorubicin hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>DOXO-EMCH</Value></Name><Name><Value>INNO-206</Value></Name><Name><Value>Doxorubicin-EMCH</Value></Name><Name><Value>aldoxorubicin (cancer), NantCell</Value></Name><Name><Value>1361644-26-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1361563-03-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="27164">Tumor Biology Center, Freiburg</CompanyOriginator><CompaniesPrimary><Company id="1104834">NantCell Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1011256">Innovive Pharmaceuticals Inc</Company><Company id="15585">CytRx Corp</Company><Company id="27164">Tumor Biology Center, Freiburg</Company></CompaniesSecondary><CrossReferences><SourceEntity id="50518" type="Drug"><TargetEntity id="330046" type="siDrug">Aldoxorubicin hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1011256" type="Company"><TargetEntity id="4295902416" type="organizationId">Cytrx Oncology Corp</TargetEntity></SourceEntity><SourceEntity id="1104834" type="Company"><TargetEntity id="5044268478" type="organizationId">Nantcell Inc</TargetEntity></SourceEntity><SourceEntity id="15585" type="Company"><TargetEntity id="4295906115" type="organizationId">CytRx Corp</TargetEntity></SourceEntity><SourceEntity id="27164" type="Company"><TargetEntity id="5035524074" type="organizationId">Universitaetsklinikum Freiburg Klinik fuer Tumorbiologie Reha GmbH</TargetEntity></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"></TargetEntity><TargetEntity id="D055752" type="MeSH"></TargetEntity><TargetEntity id="70573" type="ORPHANET"></TargetEntity><TargetEntity id="-1257831198" type="omicsDisease"></TargetEntity><TargetEntity id="614" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1507" type="ciIndication"><TargetEntity id="D021441" type="MeSH"></TargetEntity><TargetEntity id="1858" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"></TargetEntity><TargetEntity id="D005909" type="MeSH"></TargetEntity><TargetEntity id="360" type="ORPHANET"></TargetEntity><TargetEntity id="-1357419475" type="omicsDisease"></TargetEntity><TargetEntity id="678" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"></TargetEntity><TargetEntity id="D002294" type="MeSH"></TargetEntity><TargetEntity id="-1612557995" type="omicsDisease"></TargetEntity><TargetEntity id="676" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3378" type="ciIndication"><TargetEntity id="10041299" type="MEDDRA"></TargetEntity><TargetEntity id="3394" type="ORPHANET"></TargetEntity><TargetEntity id="1736" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"></TargetEntity><TargetEntity id="10033128" type="MEDDRA"></TargetEntity><TargetEntity id="D010051" type="MeSH"></TargetEntity><TargetEntity id="-1370909262" type="omicsDisease"></TargetEntity><TargetEntity id="626" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="936" type="ciIndication"><TargetEntity id="C46" type="ICD10"></TargetEntity><TargetEntity id="10023284" type="MEDDRA"></TargetEntity><TargetEntity id="D012514" type="MeSH"></TargetEntity><TargetEntity id="33276" type="ORPHANET"></TargetEntity><TargetEntity id="-1736755330" type="omicsDisease"></TargetEntity><TargetEntity id="682" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="750" type="Action"><TargetEntity id="1405" type="Mechanism">DNA-Intercalating Drugs</TargetEntity></SourceEntity><SourceEntity id="142" type="Action"><TargetEntity id="419" type="Mechanism">DNA Topoisomerase II Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01878" type="ciTarget"><TargetEntity id="99171" type="siTarget">DNA Topoisomerase II (fungal)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1261">Small-cell lung cancer</Indication><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="307">Squamous cell carcinoma</Indication><Indication id="3378">Soft tissue sarcoma</Indication><Indication id="799">Ovary tumor</Indication><Indication id="936">Kaposis sarcoma</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="142">Topoisomerase II inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="750">DNA intercalator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="1652">Prodrug</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2019-06-30T10:15:06.000Z</LastModificationDate><ChangeDateLast>2019-02-19T00:00:00.000Z</ChangeDateLast><AddedDate>2004-06-18T14:07:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1104834" linkType="Company"&gt;NantCell&lt;/ulink&gt;, under license from  &lt;ulink linkID="15585" linkType="Company"&gt;CytRx&lt;/ulink&gt; (formerly  &lt;ulink linkID="1011256" linkType="Company"&gt;Innovive Pharmaceuticals&lt;/ulink&gt;) (previously under license from the &lt;ulink linkID="27164" linkType="Company"&gt;Tumor Biology Center at the University of Freiburg&lt;/ulink&gt;), is developing a tumor-targeted doxorubicin conjugate which is  a hydrazone prodrug derivative, aldoxorubicin (DOXO-EMCH, Doxorubicin-EMCH, formerly INNO-206), a topoisomerase II inhibitor, for the potential iv treatment of cancer, primarily soft tissue sarcoma (STS) glioblastoma multiforme, small-cell lung cancer (SCLC) and pancreatic cancer    [&lt;ulink linkID="544989" linkType="reference"&gt;544989&lt;/ulink&gt;], [&lt;ulink linkID="1949073" linkType="Reference"&gt;1949073&lt;/ulink&gt;].  &lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;para&gt;In March 2014, a pivotal phase III trial was initiated in metastatic STS [&lt;ulink linkID="1538268" linkType="Reference"&gt;1538268&lt;/ulink&gt;], [&lt;ulink linkID="1538363" linkType="Reference"&gt;1538363&lt;/ulink&gt;]; in July 2016, negative topline PFS data were reported [&lt;ulink linkID="1779355" linkType="Reference"&gt;1779355&lt;/ulink&gt;]. By May 2012, a phase II trial had been initiated in  advanced pancreatic ductal adenocarcinoma [&lt;ulink linkID="1290959" linkType="Reference"&gt;1290959&lt;/ulink&gt;]. In November 2013, phase IIb trial was initiated in unresectable glioblastoma multiforme [&lt;ulink linkID="1501419" linkType="Reference"&gt;1501419&lt;/ulink&gt;]; in January 2015, positive preliminary data were reported [&lt;ulink linkID="1624235" linkType="Reference"&gt;1624235&lt;/ulink&gt;]. In January 2014, a phase II trial was initiated in Kaposi's sarcoma   [&lt;ulink linkID="1518021" linkType="Reference"&gt;1518021&lt;/ulink&gt;], [&lt;ulink linkID="1625056" linkType="Reference"&gt;1625056&lt;/ulink&gt;]; in June 2016, clinical data were reported [&lt;ulink linkID="1769884" linkType="Reference"&gt;1769884&lt;/ulink&gt;]. In September 2014, a phase IIb trial was initiated in metastatic SCLC; at that time, PFS data were expected by mid-2016 and  study completion was expected  in July 2017 [&lt;ulink linkID="1598380" linkType="Reference"&gt;1598380&lt;/ulink&gt;], [&lt;ulink linkID="1598699" linkType="Reference"&gt;1598699&lt;/ulink&gt;].  In September 2014, a phase Ib study for relapsed ovarian cancer was planned [&lt;ulink linkID="1597967" linkType="Reference"&gt;1597967&lt;/ulink&gt;]. In November 2014,  the FDA placed aldoxorubicin on partial clinical hold; no new patients were to be enrolled in trials  [&lt;ulink linkID="1613177" linkType="Reference"&gt;1613177&lt;/ulink&gt;]; in January 2015, the FDA removed the partial  hold; at that time, enrollment and dosingÂ of new patients was permitted after  approval of  revised trial protocols by IRBs of study sites [&lt;ulink linkID="1627490" linkType="Reference"&gt;1627490&lt;/ulink&gt;]. In November 2016, top line results were reported in second line  STS trial [&lt;ulink linkID="1879040" linkType="Reference"&gt;1879040&lt;/ulink&gt;]. In May 2015, the company was exploring further development of the drug in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; for pancreatic cancer [&lt;ulink linkID="1656187" linkType="Reference"&gt;1656187&lt;/ulink&gt;].  In January 2017, the NDA for STS was  to be filed in the  fourth quarter of 2017, and launch was expected in 2018 [&lt;ulink linkID="1889685" linkType="Reference"&gt;1889685&lt;/ulink&gt;]. In October 2017, NantCell was to submit IND applications combining aldoxorubicin with its immunotherapy protocols in patients with cancer [&lt;ulink linkID="1970600" linkType="Reference"&gt;1970600&lt;/ulink&gt;]. A phase I/IIb trial of aldoxorubicin in combination with Nantcell's high-affinity natural killer  cell therapy in patients with pancreatic cancer began in January 2018 [&lt;ulink linkID="1997908" linkType="Reference"&gt;1997908&lt;/ulink&gt;], [&lt;ulink linkID="1998070" linkType="Reference"&gt;1998070&lt;/ulink&gt;]. A similar I/IIb combination trial in patients with squamous cell carcinoma  began in February 2018 [&lt;ulink linkID="2002473" linkType="Reference"&gt;2002473&lt;/ulink&gt;], [&lt;ulink linkID="2002867" linkType="Reference"&gt;2002867&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;&lt;subtitle&gt;Soft tissue sarcoma&lt;/subtitle&gt;In November 2014, launch of the drug for second line STS was expected in 2017 [&lt;ulink linkID="1627490" linkType="Reference"&gt;1627490&lt;/ulink&gt;],  [&lt;ulink linkID="1608252" linkType="Reference"&gt;1608252&lt;/ulink&gt;].  In December 2015, pre-commercial launch activities were underway [&lt;ulink linkID="1717308" linkType="Reference"&gt;1717308&lt;/ulink&gt;]. In  November 2016, the company planned to file NDA with the US FDA for aldoxorubicin as a treatment for patients with relapsed or refractory STS in 2017 [&lt;ulink linkID="1879040" linkType="Reference"&gt;1879040&lt;/ulink&gt;]. In January 2017, the US FDA agreed to a   type B pre-NDA meeting. At that time, an NDA was expected to be filed in the  fourth quarter of 2017, and launch was expected in 2018 [&lt;ulink linkID="1889685" linkType="Reference"&gt;1889685&lt;/ulink&gt;]. In March 2017, the company expected to hold the type B pre-NDA meeting with the FDA in 'that month'. At that time, the company planned to provide an update of the meeting following official receipt of regulatory guidance from the FDA [&lt;ulink linkID="1908763" linkType="Reference"&gt;1908763&lt;/ulink&gt;]. In April 2017, the US FDA had reached an agreement with the company on the preparations for a NDA submission for aldoxorubicin in STS. At that time, the company expected to file a rolling NDA under section 505(b)(2) to the FDA for soft tissue sarcomas in the last quarter of 2017 [&lt;ulink linkID="1918789" linkType="Reference"&gt;1918789&lt;/ulink&gt;].Â &lt;/para&gt;&lt;para&gt;In July 2011, the drug was granted Orphan status by the FDA for soft tissue sarcomas [&lt;ulink linkID="1205505" linkType="Reference"&gt;1205505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Glioblastoma multiforme&lt;/subtitle&gt;In  September 2014, the drug was granted Orphan drug designations by the FDA for the treatment of glioblastoma multiforme [&lt;ulink linkID="1597967" linkType="Reference"&gt;1597967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the company planned to file for breakthrough therapy designation with the FDA following a phase IIb glioblastoma trial [&lt;ulink linkID="1450119" linkType="Reference"&gt;1450119&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pancreatic cancer&lt;/subtitle&gt;In April 2011, aldoxorubicin was granted Orphan  status by the FDA for pancreatic cancer [&lt;ulink linkID="1189024" linkType="Reference"&gt;1189024&lt;/ulink&gt;], [&lt;ulink linkID="1205505" linkType="Reference"&gt;1205505&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SCLC&lt;/subtitle&gt;In September 2014, the drug was granted Orphan drug designations by the FDA for the treatment of SCLC  [&lt;ulink linkID="1597967" linkType="Reference"&gt;1597967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian cancer&lt;/subtitle&gt;In September 2014, the drug was granted Orphan drug designations by the FDA for the treatment of ovarian cancer [&lt;ulink linkID="1597967" linkType="Reference"&gt;1597967&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2017, the company planned to discuss with the EMA a path for filing a MAA for aldoxorubicin [&lt;ulink linkID="1918789" linkType="Reference"&gt;1918789&lt;/ulink&gt;].Â &lt;/para&gt;&lt;para&gt;In February 2014, the COMP recommended aldoxorubicin for Orphan status for the treatment of soft tissue sarcoma [&lt;ulink linkID="1527654" linkType="Reference"&gt;1527654&lt;/ulink&gt;]. In March 2014, the drug was granted Orphan drug status by the European Commission for soft tissue sarcomas [&lt;ulink linkID="1540970" linkType="Reference"&gt;1540970&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Soft tissue sarcoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2012, the company planned to meet the FDA to initiate a a pivotal phase III global clinical trial for soft tissue sarcoma [&lt;ulink linkID="1271247" linkType="Reference"&gt;1271247&lt;/ulink&gt;]. In November 2012, CytRx held the meeting with the FDA and planned to  submit an SPA [&lt;ulink linkID="1339306" linkType="Reference"&gt;1339306&lt;/ulink&gt;]; by February 2013, the SPA had been  submitted  [&lt;ulink linkID="1387443" linkType="Reference"&gt;1387443&lt;/ulink&gt;]. In April 2013, the company reached an agreement with the FDA on the SPA to initiate the open-label pivotal trial in the US, Europe, China, Canada, Latin America and Australia, as a second-line treatment  in patients (expected n = 400) with metastatic, locally advanced or unresectable soft tissue sarcomas  [&lt;ulink linkID="1408422" linkType="Reference"&gt;1408422&lt;/ulink&gt;]. In January 2014, the company received approval from the FDA to continue dosing of patients beyond six treatment cycles until disease progression in the trial [&lt;ulink linkID="1517113" linkType="Reference"&gt;1517113&lt;/ulink&gt;]. In March 2014, patient screening was ongoing for entry in the trial [&lt;ulink linkID="1531644" linkType="Reference"&gt;1531644&lt;/ulink&gt;]. Later that month, the multicenter, randomized, open-label, safety and efficacy, phase III  trial (&lt;ulink linkID="170732" linkType="Protocol"&gt;NCT02049905&lt;/ulink&gt;; ALDOXORUBICIN-P3-STS-01)Â was initiated in patients with progressive (second line) metastatic soft tissue sarcoma (expected n = 	400) to compare the drug to physicians' choice chemotherapy [&lt;ulink linkID="1538268" linkType="Reference"&gt;1538268&lt;/ulink&gt;], [&lt;ulink linkID="1538363" linkType="Reference"&gt;1538363&lt;/ulink&gt;]. In December 2015, enrollment  (n = 433) was completed [&lt;ulink linkID="1717308" linkType="Reference"&gt;1717308&lt;/ulink&gt;]. In April 2016, the trial achieved 191 target events, triggering a statistical data analysis  [&lt;ulink linkID="1748437" linkType="Reference"&gt;1748437&lt;/ulink&gt;]. In July 2016, topline data from the trial were reported. Data demonstrated that there was no   significant difference between aldoxorubicin and investigator's choice therapy for PFS, with a median of 4.17   and 4.04 months, respectively, for the study's primary endpoint.Â However, objective response rate  and disease control rate  showed a near doubling in the aldoxorubicin arm compared to investigator's choice, including in patients who previously received treatment with doxorubicin.Â  Disease control rate for aldoxorubicin was significantly greater than investigator's choice therapy in the intent-to-treat population   and in patients who received prior doxorubicin. Patients continue to be followed for overall survival (OS), a secondary endpoint of the trial.  CytRx expected to conduct a second analysis, which would include longer patient follow-up and allow for greater maturation of all endpoints. At that time,   results from second analysis and an end-of-phase III meeting with the  FDA  were expected in 4Q16 [&lt;ulink linkID="1779355" linkType="Reference"&gt;1779355&lt;/ulink&gt;]. In November 2016 , topline results demonstrated a statistically significant improvement in progression-free survival (PFS) between aldoxorubicin and investigator's choice therapy in 246 patients with leiomyosarcoma and liposarcoma (p=0.007). The hazard ratio (HR) was 0.62, represented a 38% reduction in the risk of tumor progression for patients.Â Further, the drug had performed better and showed a good PFS over investigator's choice in 312 patients treated inÂ North AmericaÂ (p=0.028). Significant improvement in the disease control rate of 29.4 vs 20.5% 	was observed in the entire study population; and 32.9 vs 19.2% in North America patient. At that time, the company expected to report overall survival data in 2017Â [&lt;ulink linkID="1879040" linkType="Reference"&gt;1879040&lt;/ulink&gt;]. In March 2017, the company expected to report data from the trial to the FDA in 'that quarter of the year'. At that time, the company also expected to present the results in a peer-reviewed forum 'in the coming months' [&lt;ulink linkID="1908763" linkType="Reference"&gt;1908763&lt;/ulink&gt;]. In June 2017, further data were presented at 53rd ASCO meeting in Chicago, IL. In ITT population treated with aldoxorubicin and investigatorsâ choice drugs median overall survival observed was 12.88 (p= 0.8555) and 12.16 months, respectively, hazard ratio was 0.97. In L-sarcomas population, ORR was 41.7 (p = 0.0161) and 27.0%, respectively [&lt;ulink linkID="1932101" linkType="Reference"&gt;1932101&lt;/ulink&gt;] [&lt;ulink linkID="1928489" linkType="Reference"&gt;1928489&lt;/ulink&gt;]. In June 2018, similar results were published [&lt;ulink linkID="2047181" linkType="Reference"&gt;2047181&lt;/ulink&gt;], [&lt;ulink linkID="2047526" linkType="Reference"&gt;2047526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase IIb&lt;/subtitle&gt;In December 2011, an international, open-label phase IIb trial was initiated in patients (expected n = 105) with metastatic, locally advanced or unresectable soft tissue sarcoma. By that time, the trial was presumed to be initiated in Hungary, Romania, Ukraine, Russia, India and Australia [&lt;ulink linkID="1250696" linkType="Reference"&gt;1250696&lt;/ulink&gt;]. In July 2012, enrollment completion and data analysis in the phase II study to compare aldoxorubicin head-to-head with doxorubicin as a first-line treatment were expected in 2013 [&lt;ulink linkID="1310956" linkType="Reference"&gt;1310956&lt;/ulink&gt;]; in March 2013, the company expected results in the second half of 2013 [&lt;ulink linkID="1390581" linkType="Reference"&gt;1390581&lt;/ulink&gt;]. In May 2013, the  independent Data Safety Monitoring Committee (DSMC) recommended conducting the trial through completion [&lt;ulink linkID="1416028" linkType="Reference"&gt;1416028&lt;/ulink&gt;]. In June 2013, the company completed the target enrollment of 105 patients and the patients were randomized into two groups to receive aldoxorubicin twice as many as doxorubicin in sites including the US [&lt;ulink linkID="1443702" linkType="Reference"&gt;1443702&lt;/ulink&gt;]. In October 2013, preliminary results were presented  at the Connective Tissue Oncology Society 18th Annual Meeting in New York, NY, USA. In the study, 123 patients were randomized in 2:1 ratio to receive 350 mg/m2 of iv aldoxorubicin or 75 mg/m2Â of iv doxorubicin, every three weeks for six cycles. Results demonstrated that overall response rate for aldoxorubicin was 22% compared to doxorubicin (0%). Also, 32% of the patients treated with aldoxorubicin had progressive disease compared to 50% for doxorubicin [&lt;ulink linkID="1494708" linkType="Reference"&gt;1494708&lt;/ulink&gt;]. In December 2013, topline data were reported from the multicenter globalÂ trial. Both investigator assessment and central lab review showed 80-100% improvement in progression-free survival (PFS) among patients treated with aldoxorubicin compared to doxorubicin. In an intent-to-treat analysis, the investigator-assessed median PFS was 8.4 and 4.7 months for aldoxorubicin and doxorubicin, respectively (p=0.0002) and the blinded central lab review showed that, median PFS was 5.7 and 2.8 months for aldoxorubicin and doxorubicin, respectively  (p=0.018). Investigator assessment showed that, 6-month PFS was 67.1 and 36.1% for aldoxorubicin and doxorubicin-treated patients, respectively. Blinded central lab review showed that, 6-month PFS was 46.8 and 23.7% for aldoxorubicin and doxorubicin-treated patients, respectively. Investigator assessment showed that, the overall response rate was 25.4% for aldoxorubicin subjects (2.7% complete response and 22.7% partial response) and 5.4% for doxorubicin subjects (0% complete response and 5.4% partial response). Blinded central lab review showed that, 23% of aldoxorubicin subjects had a partial response while 0% of doxorubicin subjects exhibited any objective response. Aldoxorubicin was tolerated [&lt;ulink linkID="1508145" linkType="Reference"&gt;1508145&lt;/ulink&gt;]. In January 2014,  results from additional statistical analyses were reported. A reduction of 63 and 41% in the risk of disease progression (hazard ratios 0.37 and 0.59 respectively) was observed for investigator scans and central lab scans respectively. Kaplan-Meier analysis of the trial results demonstrated significant improvement in aldoxorubicin-treated subjects compared to doxorubicin-treated subjects. At that time, full study results were expected to be presented at the American Society for Clinical Oncology (ASCO) Meeting,Chicago, IL in June 2014 [&lt;ulink linkID="1513929" linkType="Reference"&gt;1513929&lt;/ulink&gt;]. By March 2014, the study had been completed [&lt;ulink linkID="1531644" linkType="Reference"&gt;1531644&lt;/ulink&gt;]. In June 2014, further data from the trial (&lt;ulink linkID="84197" linkType="Protocol"&gt;NCT01514188&lt;/ulink&gt;) were presented at the  50th ASCO meeting in Chicago, IL. In both investigator and blinded independent reviews, progressive free survival and overall response rates of aldoxorubicin were significantly higher when compared with doxorubicin [&lt;ulink linkID="1561048" linkType="Reference"&gt;1561048&lt;/ulink&gt;] [&lt;ulink linkID="1562861" linkType="Reference"&gt;1562861&lt;/ulink&gt;]. In October 2014, similar data from the 103-patient trial were presented at the 2014 Connective Tissue Oncology Society (CTOS) Annual Meeting in Berlin, Germany. Further, data showed improvements in tumor shrinkage in treated patients [&lt;ulink linkID="1603018" linkType="Reference"&gt;1603018&lt;/ulink&gt;]. In January 2015, overall survival results and the secondary endpoint data from the 123 patients treated in the trial were reported. Data demonstrated that aldoxorubicin-treated patients showed 27% reduction in the risk of death compared to doxorubicin-treated patients, 41% likelihood of surviving more than 2 years was found in aldoxorubicin-treated patients compared to 20% probability for doxorubicin-treated patients, the median overall survival was 16 months in aldoxorubicin-treated patients compared to 14 months in doxorubicin-treated patients, the median PFS increased approximately 79% to 8.4 months in aldoxorubicin-treated patients compared to 4.7 months with doxorubicin and a blinded central radiology review demonstrated the median PFS increased approximately 104% to 5.7 months in aldoxorubicin-treated patients compared to 2.8 months with doxorubicin thus met the study's primary endpoint. Furthermore, the secondary endpoint results demonstrated that PFS at 6 months increased by approximately 86% in scans read by trial investigators and approximately 100% in blinded central radiology review compared to doxorubicin. The objective response rate was 21.7% for aldoxorubicin compared to 5.0% for doxorubicin in investigator trials and 23.8% of aldoxorubicin subjects had a partial response compared to 0.0% in doxorubicin subjects by blinded central lab review. In treatment-naive patients, the median overall survival was found to be 16.4 months for aldoxorubicin-treated patients compared to 14.6 months for doxorubicin treated patients  [&lt;ulink linkID="1628311" linkType="Reference"&gt;1628311&lt;/ulink&gt;], [&lt;ulink linkID="1639985" linkType="Reference"&gt;1639985&lt;/ulink&gt;]. In September 2015, similar data were published. Aldoxorubicin showed significantly superior efficacy over doxorubicin by  improving rates of 6-month PFS and tumor response [&lt;ulink linkID="1696758" linkType="Reference"&gt;1696758&lt;/ulink&gt;], [&lt;ulink linkID="1696442" linkType="Reference"&gt;1696442&lt;/ulink&gt;].  In June 2018, similar results were published [&lt;ulink linkID="2047181" linkType="Reference"&gt;2047181&lt;/ulink&gt;], [&lt;ulink linkID="2047526" linkType="Reference"&gt;2047526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2009, an open-label, phase II study of INNO-206, administered once every 3 weeks for four consecutive cycles, in 50 patients with advanced soft tissue sarcomas, who have failed surgery and radiation, was planned. The trial would be conducted in the US, Europe and India. Overall tumor response and progression free survival would be assessed. Enrollment was expected to be completed approximately 12 months after  trial  initiation [&lt;ulink linkID="1060096" linkType="Reference"&gt;1060096&lt;/ulink&gt;]. By March 2010,  the study was expected to begin in the second half of 2010 [&lt;ulink linkID="1070044" linkType="Reference"&gt;1070044&lt;/ulink&gt;], [&lt;ulink linkID="1082211" linkType="Reference"&gt;1082211&lt;/ulink&gt;]. However, in January 2011, the company planned to initiate phase II trials following an abbreviated safety trial [&lt;ulink linkID="1160758" linkType="Reference"&gt;1160758&lt;/ulink&gt;]; in March 2011, the trial for soft tissue sarcomas was expected to begin in the second  half of 2011 [&lt;ulink linkID="1175478" linkType="Reference"&gt;1175478&lt;/ulink&gt;]; in July 2011, a phase IIb trial in late-stage soft tissue sarcoma patients was expected to begin in the second  half of 2011 after the completion of the ongoing  phase Ib  trial in solid tumors  [&lt;ulink linkID="1205505" linkType="Reference"&gt;1205505&lt;/ulink&gt;]. In October 2011, the international phase IIb trial was expected to be initiated in advanced soft tissue sarcoma patients in December 2011 [&lt;ulink linkID="1234968" linkType="Reference"&gt;1234968&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase Ib/II&lt;/subtitle&gt;In September 2014, enrollment was initiated in an open-label, multisite, dose-escalation, phase Ib/II trial (&lt;ulink linkID="210154" linkType="Protocol"&gt;NCT02235701&lt;/ulink&gt;; ALDOXORUBICIN-P1/2-STS-03), designed to investigate the preliminary safety and activity of aldoxorubicin and ifosfamide/&lt;ulink linkID="24142" linkType="Drug"&gt;mesna&lt;/ulink&gt; in patients (expected n = 30) with locally advanced, unresectable, and/or metastatic STS, chondrosarcoma or certain osteosarcomas. At that time, enrollment was expected to be complete by the third quarter of 2015, with the trial completion in April 2016 [&lt;ulink linkID="1592121" linkType="Reference"&gt;1592121&lt;/ulink&gt;], [&lt;ulink linkID="1656188" linkType="Reference"&gt;1656188&lt;/ulink&gt;]. In March 2015, enrollment was expected to be completed in the second half of 2015 [&lt;ulink linkID="1639985" linkType="Reference"&gt;1639985&lt;/ulink&gt;]. In May 2015, interim analysis data were reported from a dose escalation trial. Data demonstrated that the combination appeared to be well tolerated, and even at the lowest dose level of aldoxorubicin (170 mg/m2), impressive tumor responses had been observed  in seven patients with osteosarcoma and a variety of soft tissue sarcomas. First patient with osteosarcoma treated with ifosfamide plus aldoxorubicin had a PET-demonstrated complete tumor response after only five cycles of the combination that had persisted for over six months. At that time, the trial was expected to be completed in the second half of 2015 [&lt;ulink linkID="1656187" linkType="Reference"&gt;1656187&lt;/ulink&gt;]. In March 2016, the trial was expected to complete in the second half of 2016 [&lt;ulink linkID="1742712" linkType="Reference"&gt;1742712&lt;/ulink&gt;]. In June 2016, further clinical data were presented at the 52nd ASCO meeting in Chicago, IL. Partial response, stable disease, and disease progression were reported in seven, ten and one patient, respectively. Left ventricular ejection fraction &amp;lt; 50% was not reported in any subject at any time. Overall, responses observed were durable [&lt;ulink linkID="1769996" linkType="Reference"&gt;1769996&lt;/ulink&gt;]. In October 2016, further data were presented at the ESMO 2016 Congress in Copenhagen, Denmark. Of 24 evaluable patients, 8 had had a partial response (PR), 15 had stable disease (SD) and only 1 had progressive disease, with an overall disease control rate (PR + SD) of 95%. Greater than 6 months was the median duration of progression-free survival [&lt;ulink linkID="1805773" linkType="Reference"&gt;1805773&lt;/ulink&gt;]. In November 2016, interim results from the trial were presented at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)  inÂ Lisbon, Portugal. Of  36 of 42 evaluable patients received either 170 (n =7) or 250 (n=29) mg/m2Â of aldoxorubicin plus ifosfamide and mesna, 39% patient achieved a partial response of the target lesion by RECIST 1.1 criteria, 58% had stable disease, and one patient had progressive disease. Also, 40% of the sarcoma patients achieved a partial response of the target lesion by RECIST criteria, and half of those had &amp;gt;50% shrinkage of their tumors. At that time, the trial was expanded to enroll additional patients   [&lt;ulink linkID="1873508" linkType="Reference"&gt;1873508&lt;/ulink&gt;]. In March 2017, updated data from the trial were expected to be reported in 2017 [&lt;ulink linkID="1908763" linkType="Reference"&gt;1908763&lt;/ulink&gt;]. In June 2017, further data were presented at 53rd ASCO meeting in Chicago, IL. In patients with 2 cycles of aldoxorubicin + ifosfamide/mesna, 73% of tumor reduction was observed, while over 14 cycles, significant calcification and over 20% of tumor reduction was observed. In grade 3/4 patients treated with aldoxorubicin (170 and 250 mg/m2), treatment-emergent adverse events (AEs) like neutropenia, anemia, thrombocytopenia, febrile neutropenia, leucopenia, nausea/vomiting, mucositis and decreased WBC were reported [&lt;ulink linkID="1931810" linkType="Reference"&gt;1931810&lt;/ulink&gt;] [&lt;ulink linkID="1928489" linkType="Reference"&gt;1928489&lt;/ulink&gt;].  In June 2018, similar results were published [&lt;ulink linkID="2047181" linkType="Reference"&gt;2047181&lt;/ulink&gt;], [&lt;ulink linkID="2047526" linkType="Reference"&gt;2047526&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In September 2011,  CytRx  tripled the number of patients in a phase Ib clinical trial that was being carried out primarily in patients with advanced soft tissue sarcomas who had failed standard therapies, designating it a phase Ib/II trial in STS. By that time, 6 patients had already been treated at the dose planned for phase IIb trials, out of a total of 13 enrolled in the trial, and the company  planned to enroll an additional 12 patients in the phase II portion of the phase Ib/II trial [&lt;ulink linkID="1225858" linkType="Reference"&gt;1225858&lt;/ulink&gt;]. Later, in September 2011, the phase Ib portion, which included 12 patients, was completed. In October 2011, initial favorable response and safety data from the ongoing trial were reported. Of five patients, one  had a partial tumor response of greater than 30% tumor shrinkage and four  had stable disease, following four cycles of INNO-206 administration at the maximum tolerated dose. A large, painful, oral sarcoma was greatly reduced in a patient following a single administration of aldoxorubicin. Out of 12 additional patients, 6 were enrolled. At that time, final data were expected to be presented at  the ASCO meeting in Chicago, IL, in June 2012 [&lt;ulink linkID="1234968" linkType="Reference"&gt;1234968&lt;/ulink&gt;]. By June 2012, the trial had been completed [&lt;ulink linkID="1300585" linkType="Reference"&gt;1300585&lt;/ulink&gt;]. Later that month, data from 25 patients were presented at the 48th ASCO meeting in Chicago, IL. Of the 13 evaluable patients treated at 350 mg/m2, 5 showed partial response, 7 had stable disease and 1 had progressive disease. The estimated median progression-free survival duration was 6.43 months. In 61.5% of patients, tumor shrinkage was seen, with  50 and 100% tumor reduction seen in one patient each. The MTD of INNO-206 was determined to be 350 mg/m2 (260 mg/m2 doxorubicin equivalents) administered q3w for up to eight cycles [&lt;ulink linkID="1295774" linkType="Reference"&gt;1295774&lt;/ulink&gt;]; in October 2012, similar data were presented  at the 37th European Society for Medical Oncology Congress in Vienna, Austria [&lt;ulink linkID="1325907" linkType="Reference"&gt;1325907&lt;/ulink&gt;], [&lt;ulink linkID="1327590" linkType="Reference"&gt;1327590&lt;/ulink&gt;]; in November 2012, similar data were presented at the Connective Tissue Oncology Society 17th Annual Meeting in Prague, Czech Republic [&lt;ulink linkID="1341177" linkType="Reference"&gt;1341177&lt;/ulink&gt;]. In March 2014,  updated analysis data were reported and median progression-free survival in patients has reached over 17 months  [&lt;ulink linkID="1538268" linkType="Reference"&gt;1538268&lt;/ulink&gt;]; in May 2014, updated progression-free survival and overall survival data after 8 cycles of aldoxorubicin treatment, from the completed trial were presented on the company's Research and Development Day at the Harvard Club in New York City, NY. The data demonstrated, that maximum tolerated dose of aldoxorubicin (350mg/m2) increased the median progression-free survival in patients with 6 patients had stable disease. Median progression-free survival had doubled to 11 months and median overall survival (OS) was 17 months. Two patients experienced no progression of disease for 23 and 15 months, respectively. The drug was well tolerated [&lt;ulink linkID="1553066" linkType="Reference"&gt;1553066&lt;/ulink&gt;]. In October 2014, similar data were published. Further, data demonstrated that the median PFS and OS was 11.25 and 21.71 months, respectively. In the MTD dosing cohort, 12 of 13 patients had received prior chemotherapy and completed a median of eight dosing cycles, and found that 9 patients had a   partial response or stable disease for &amp;gt;/= 4 months [&lt;ulink linkID="1603713" linkType="Reference"&gt;1603713&lt;/ulink&gt;], [&lt;ulink linkID="1603446" linkType="Reference"&gt;1603446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other Studies&lt;/subtitle&gt;In June 2018, clinical data from phase II (INNO-206-P2-STS-01) and phase III (P3-STS-01) studies which evaluated the cardiac safety of aldoxrubicin administration, with cumulative dose exceeding doxorubicin equivalence of 1000 mg/m2 (approximately 1350 mg/m2 aldoxorubicin) were presented at the 54th ASCO Annual Meeting in Chicago, IL. Ventricular ejection fractions ranged from 45 to 75 and 50 to 77% at baseline and at the end of treatment, respectively, median being 60% both at the beginning and the end of treatment. The doxorubicin dose prior to aldoxorubicin treatment in 11 patients was 158 mg/m2. There were no clinically significant cardiac problems despite administration of median cumulative dose of doxorubicin equivalents of 2080 mg/m2 [&lt;ulink linkID="2043949" linkType="Reference"&gt;2043949&lt;/ulink&gt;], [&lt;ulink linkID="2035343" linkType="Reference"&gt;2035343&lt;/ulink&gt;], [&lt;ulink linkID="2042341" linkType="Reference"&gt;2042341&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Small cell lung cancer&lt;/subtitle&gt;In March 2014, a global phase IIb trial of aldoxorubicin as a second-line treatment for SCLC was planned [&lt;ulink linkID="1531644" linkType="Reference"&gt;1531644&lt;/ulink&gt;]. In September 2014, the randomized, parallel assignment, open-label, safety/efficacy phase IIb trial (&lt;ulink linkID="206619" linkType="Protocol"&gt;NCT02200757&lt;/ulink&gt;; ALDOXORUBICIN-P2-SCLC-01) was initiated to compare aldoxorubicin to &lt;ulink linkID="4577" linkType="Drug"&gt;topotecan&lt;/ulink&gt;, in patients (expected n = 132) with metastatic SCLC who either relapsed or were refractory to prior chemotherapy, in the US, Spain, Italy and Hungary. At that time, the study was expected to be completed in July 2017 [&lt;ulink linkID="1598380" linkType="Reference"&gt;1598380&lt;/ulink&gt;], [&lt;ulink linkID="1598699" linkType="Reference"&gt;1598699&lt;/ulink&gt;]. In September 2015, initial data were presented at the IASLC 16th World conference on Lung Cancer in Denver, CO. The estimated median progression free survival was 6.5 and 3.5 months in the aldoxorubicin and topotecan groups, respectively. Neutropenia, thrombocytopenia, anemia, febrile neutropenia, nausea/vomiting, mucositis, fatigue, alopecia and hypoalbuminemia were possible adverse events reported [&lt;ulink linkID="1693905" linkType="Reference"&gt;1693905&lt;/ulink&gt;]. By July 2016, topline data were expected in 4Q16 [&lt;ulink linkID="1784125" linkType="Reference"&gt;1784125&lt;/ulink&gt;]. In September 2016, enrollment was completed with 132 patients recruited in the trial [&lt;ulink linkID="1794277" linkType="Reference"&gt;1794277&lt;/ulink&gt;]. In March 2017, the company expected to report topline data by the end of the second quarter of 2017 [&lt;ulink linkID="1908763" linkType="Reference"&gt;1908763&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2007, a phase II trial (&lt;ulink linkID="36775" linkType="Protocol"&gt;NCT00472771&lt;/ulink&gt;, INNO-206-P2) in patients with extensive SCLC was planned.  The non-randomized, open-label, uncontrolled, single-group study would enroll 40 patients following first line platinum therapy.  The primary outcome was overall response rate including complete and partial responses [&lt;ulink linkID="797606" linkType="Reference"&gt;797606&lt;/ulink&gt;]; in September 2008, the trial was not yet open for recruitment  [&lt;ulink linkID="797606" linkType="Reference"&gt;797606&lt;/ulink&gt;].  However, in November 2008, the trial was terminated due to clinical trial material production delays  [&lt;ulink linkID="797606" linkType="Reference"&gt;797606&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Glioblastoma&lt;/subtitle&gt;In July 2013, CytRx planned to start a phase IIb trial in relapsed glioblastoma [&lt;ulink linkID="1450119" linkType="Reference"&gt;1450119&lt;/ulink&gt;], [&lt;ulink linkID="1461771" linkType="Reference"&gt;1461771&lt;/ulink&gt;]. In November 2013, a randomized, open-label, multicenter, efficacy and safetyÂ phase II trial was initiated in patients (expected n = 28) with unresectable glioblastoma multiforme [&lt;ulink linkID="1501419" linkType="Reference"&gt;1501419&lt;/ulink&gt;]. In January 2014, the first patients was dosed in an  interventional, pilot, singleÂ groupÂ assigned trial (&lt;ulink linkID="164198" linkType="Protocol"&gt;NCT02014844&lt;/ulink&gt;; ALDOXORUBICIN-P2-GBM-01).  The trial was expected to complete in  June 2015 [&lt;ulink linkID="1515462" linkType="Reference"&gt;1515462&lt;/ulink&gt;], [&lt;ulink linkID="1515619" linkType="Reference"&gt;1515619&lt;/ulink&gt;].  In January 2015, interim data from 12 patients were reported. Data demonstrated that  treatment with aldoxorubicin showed favorable tolerability, prolonged stable disease, and tumor shrinkage in several patients including a complete response and also provided evidence that aldoxorubicin allowed doxorubicin to cross the blood-brain barrier to treat tumors [&lt;ulink linkID="1624235" linkType="Reference"&gt;1624235&lt;/ulink&gt;]. In March 2015, result from a 54 year old male patient  who had completed treatment with radiation and &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; more than two years prior enrollment into the trial   with recurrent left parietal lobe glioblastoma multiforme were published. Data demonstrated progressive tumor growth prior to debulking procedure. However, histopathological assessment of the tissue following a subsequent tumor debulking procedure showed no evidence of recurrent glioblastoma throughout the entire surgical specimen.  Based on these results, investigators believed that the presence of tumor seen in the MRI scans post aldoxorubicin treatment likely represents pseudo-progression, commonly seen in CNS malignancies undergoing radiation therapy, and might reflect aldoxorubicin's ability to allow doxorubicin to enter the brain tumor and induce tumor necrosis [&lt;ulink linkID="1655306" linkType="Reference"&gt;1655306&lt;/ulink&gt;], [&lt;ulink linkID="1655129" linkType="Reference"&gt;1655129&lt;/ulink&gt;]. In May 2015, further data were reported. Two complete responses (11%) were observed after treatment with aldoxorubicinÂ [&lt;ulink linkID="1662231" linkType="Reference"&gt;1662231&lt;/ulink&gt;]. In November 2015, enrollment was completed. Of 28 patients, 16 continue to be followed for survival with 6 patients still receiving aldoxorubicin treatment.Â  Clear evidence of pseudo-progression was observed in the tumor lesions of at least 4 patients either after surgical debulking or by dynamic susceptibility contrast MRI.Â  Other patients showed extensive tumor necrosis on pathology with small amounts of residual tumor.  Aldoxorubicin was well tolerated at both dose levels.  By that time, median overall survival   had not been  reached. Â An Advisory Board of neuro-oncology experts  concluded   that a randomized, comparative pivotal trial combining aldoxorubicin with &lt;ulink linkID="8047" linkType="Drug"&gt;Avastin&lt;/ulink&gt; compared to Avastin in patients who have relapsed after initial therapy was warranted and the company planned to discuss the pivotal trial protocol with regulatory agencies, like the FDA, after obtaining final data from the phase II trial  [&lt;ulink linkID="1715505" linkType="Reference"&gt;1715505&lt;/ulink&gt;]. In June 2016, survival data were presented at the 52nd ASCO meeting in Chicago, IL. Median overall survival was 8.6 months. Treatment with aldoxorubicin led to tumor shrinkage of 26.2% reduction in bidimensional measurements and improvements in midline shift and mass effect on lateral ventricles. A significant reduction in T2 flair signal was also observed [&lt;ulink linkID="1766332" linkType="Reference"&gt;1766332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;AIDS-related Kaposi's sarcoma&lt;/subtitle&gt;In October 2013, CytRx planned to initiate a phase II trial  in AIDS-related Kaposi's sarcoma. The trial was expected to  enroll up to 30 patients at the &lt;ulink linkID="1066982" linkType="Company"&gt;LSU Health Science Center&lt;/ulink&gt;, New Orleans [&lt;ulink linkID="1493506" linkType="Reference"&gt;1493506&lt;/ulink&gt;]. In January 2014, the pilot, open-label trial (&lt;ulink linkID="166459" linkType="Protocol"&gt;NCT02029430&lt;/ulink&gt;; ALDOXORUBICIN-P2-KS-01) was initiated in patients (expected n = 30) with Kaposi's sarcoma to evaluate  efficacy, safety and intratumoral kinetics of aldoxorubicin as a first line treatment.  At that time, the study was expected to complete in June 2016  [&lt;ulink linkID="1518021" linkType="Reference"&gt;1518021&lt;/ulink&gt;], [&lt;ulink linkID="1518139" linkType="Reference"&gt;1518139&lt;/ulink&gt;]. In January 2015, interim results from 9-patients were reported. The patients were randomized and received 50, 100 or 150 mg/m2  of  iv infusion of drug in three equally sized treatment arms in 30 min. All the patients showed a decrease in the number of  KS virus DNA  expressing cancer cells   and  skin lesions. Out of 6 patients with lung tumor, 4 patients (66%) were observed  either with a partial or complete response and no tumor progression was observed in KS patients. The drug was tolerable [&lt;ulink linkID="1625056" linkType="Reference"&gt;1625056&lt;/ulink&gt;]. In May 2015, further data were presented at the 51st ASCO meeting in Chicago, IL. 									Improvements in quality of life were noticed in a subset of patients, and all patients exhibited either improvement or stability in immunological and virological HIV treatment parameters. Aldoxorubicin was tolerated and  therapeutically active [&lt;ulink linkID="1665472" linkType="Reference"&gt;1665472&lt;/ulink&gt;]. In June 2015, the company presented interim data at the 18th International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents on July 01, 2015, atÂ Hollywood, FL. Preliminary analyses of nine patients who received at least six cycles of drug showed that, six (67%) demonstrated a partial responseÂ at the end of study (EOS) visitÂ  and 7 (78%) demonstrated a partial responseÂ within 4 months of EOS. The drug was found to be well tolerated and uptake of doxorubicin in KS lesions was observed [&lt;ulink linkID="1673994" linkType="Reference"&gt;1673994&lt;/ulink&gt;].  In August 2015, further results from the trial were expected by the end of 2015 [&lt;ulink linkID="1683077" linkType="Reference"&gt;1683077&lt;/ulink&gt;]. In June 2016, similar clinical data were presented at the 52nd ASCO meeting in Chicago, IL [&lt;ulink linkID="1769884" linkType="Reference"&gt;1769884&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pancreatic  cancer&lt;/subtitle&gt;In January 2018, the first patient  was dosed in the phase Ib portion of an open-label, single group assigned phase Ib/II  trial (&lt;ulink linkID="324390" linkType="Protocol"&gt;NCT03387098&lt;/ulink&gt;; QUILT-3.070)   in  the US, in patients (expected n = 173) with metastatic pancreatic cancer who have progressed on or after previous standard-of-careÂ chemotherapy, to assess the safety and efficacy of &lt;ulink linkID="106444" linkType="Drug"&gt;NANT Pancreatic Cancer Vaccine&lt;/ulink&gt; in combination with other anti cancer agents including aldoxorubicin. At that time, the trial was expected to complete in December 2019 [&lt;ulink linkID="1998070" linkType="Reference"&gt;1998070&lt;/ulink&gt;],  [&lt;ulink linkID="1997908" linkType="Reference"&gt;1997908&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015,  the company was exploring further development of the drug in combination with &lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine&lt;/ulink&gt; for pancreatic cancer.  At that time, the company was planning to begin enrollment in the second half of 2015 [&lt;ulink linkID="1656187" linkType="Reference"&gt;1656187&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2012, a trial had been initiated in patients with advanced pancreatic ductal adenocarcinomas [&lt;ulink linkID="1290959" linkType="Reference"&gt;1290959&lt;/ulink&gt;]. In June 2012, the trial was expected to enroll up to 27 patients [&lt;ulink linkID="1301102" linkType="Reference"&gt;1301102&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2010, a phase II, German, open-label, prospective, multicenter, single-arm, 15-patient trial for metastatic or inoperative (unresectable ductal) pancreatic cancer not previously treated or which had failed gemcitabine therapy was planned. The patients would receive iv doses of the drug every 3 weeks for 6 cycles. Overall survival, progression-free-survival and objective overall response rates would be assessed [&lt;ulink linkID="1066887" linkType="Reference"&gt;1066887&lt;/ulink&gt;]. In March 2010, the study was expected to begin in the first half of 2010 [&lt;ulink linkID="1070044" linkType="Reference"&gt;1070044&lt;/ulink&gt;],  [&lt;ulink linkID="1082211" linkType="Reference"&gt;1082211&lt;/ulink&gt;]. However, in January 2011, the company planned to initiate the trial following an abbreviated safety trial [&lt;ulink linkID="1160758" linkType="Reference"&gt;1160758&lt;/ulink&gt;]; in March 2011, the trial was expected to begin in the second  half of 2011 [&lt;ulink linkID="1175478" linkType="Reference"&gt;1175478&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastric cancer&lt;/subtitle&gt;In November 2009, a phase II, open-label study to assess INNO-206 as a second-line treatment in 50 patients with advanced gastric cancer, who had failed previous treatments such as surgery and chemotherapy with drugs other than doxorubicin, was planned. Patients would receive INNO-206 every 3 weeks for four cycles. Overall tumor response and progression-free survival would be assessed. A further 25 patients could be enrolled, depending on initial results. The trial would be conducted in the US, Europe, India and the Far East. It was expected that enrollment would be completed within 12 months of the start of the study [&lt;ulink linkID="1058160" linkType="Reference"&gt;1058160&lt;/ulink&gt;].Â By January 2010,  the study was expected to begin in the second half of 2010 [&lt;ulink linkID="1070044" linkType="Reference"&gt;1070044&lt;/ulink&gt;], [&lt;ulink linkID="1082211" linkType="Reference"&gt;1082211&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Squamous  cell carcinoma&lt;/subtitle&gt;In February  2018, the first patient  was dosed in the phase Ib portion of an open-label, single group assigned phase Ib/II  trial      (&lt;ulink linkID="324461" linkType="Protocol"&gt;NCT03387111&lt;/ulink&gt;; QUILT-3.090)Â in  the US, in patients (expected n = 65) with either head and neck or non-small cell lung cancer who have progressed on or after previous standard-of-careÂ chemotherapy, to assess the safety and efficacy of &lt;ulink linkID="106444" linkType="Drug"&gt;NANT Pancreatic Cancer Vaccine&lt;/ulink&gt; in combination with other anti cancer agents including aldoxorubicin. At that time, the estimated study completion date was  December 2019  [&lt;ulink linkID="2002473" linkType="Reference"&gt;2002473&lt;/ulink&gt;], [&lt;ulink linkID="2002867" linkType="Reference"&gt;2002867&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian cancer&lt;/subtitle&gt;In September 2014, a phase Ib combination study of aldoxorubicin and gemcitabine for relapsed ovarian cancer was planned [&lt;ulink linkID="1597967" linkType="Reference"&gt;1597967&lt;/ulink&gt;]. In May 2015, the company was planning to begin enrollment in the second half of 2015 [&lt;ulink linkID="1656187" linkType="Reference"&gt;1656187&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I studies in solid tumors&lt;/subtitle&gt;In October 2017, NantCell was to submit IND applications combining aldoxorubicin with its immunotherapy protocols in patients with cancers who were no longer responding or never responded to standard therapy and had progressed. The trials would employ an adaptive design which would allow for expansion of treatment cohorts and modification of patient treatments based on tumor profiling and individual patient responses over time [&lt;ulink linkID="1970600" linkType="Reference"&gt;1970600&lt;/ulink&gt;]. In November 2017, the company was planning to submit an IND  applications aldoxorubicin with its immunotherapy protocols in patients with   pancreatic and breast cancer  [&lt;ulink linkID="1979638" linkType="Reference"&gt;1979638&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, data from three phase I trials (INNO-206-P1-MTD-01, ALDOXORUBICIN-P1-MTD-02, ALDOXORUBICIN-P1-PK-01), three phase II trials (INNO-206-P2-STS-01, ALDOXORUBICIN-P2-KS-01, ALDOXORUBICIN-P2-GBM-01), and one phase III trial (ALDOXORUBICIN-P3-STS-01), which reviewed longer term cardiac safety of aldoxorubicin in patients (n = 142) with advanced solid tumors, soft tissue sarcoma, Kaposi's sarcoma, glioblastoma, were presented at the 51st ASCO meeting in Chicago, IL. Progression free survival (PFS) was 8.4, 4.7, and 3.7 months and PFS at 6 months was 45.7, 22.9, and 99.6% in intent-to-treat patients treated with aldoxorubicin, doxorubicin, and improvement over doxorubicin, respectively [&lt;ulink linkID="1663642" linkType="Reference"&gt;1663642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2014, an openÂ label, non-randomized, multisite, 	single group assigned, phase Ib trial (&lt;ulink linkID="210091" linkType="Protocol"&gt;NCT02235688&lt;/ulink&gt;; ALDOXORUBICIN-P1-MTD-03) was initiated in the US in patients (expected n = 30), with metastatic solid tumors to evaluate the preliminary safety and efficacy of the drug in combination with gemcitabine.Â The trial was expected to complete in April 2016. At that time, the enrollment was expected to be completed in the third quarter of 2015 [&lt;ulink linkID="1601191" linkType="Reference"&gt;1601191&lt;/ulink&gt;]. In October 2014, enrollment was initiated [&lt;ulink linkID="1600918" linkType="Reference"&gt;1600918&lt;/ulink&gt;]. In March 2015, enrollment was expected to be completed in the second half of 2015 [&lt;ulink linkID="1639985" linkType="Reference"&gt;1639985&lt;/ulink&gt;]. In May 2015, interim analysis data were reported from the seven patients. Data demonstrated that the combination appeared to be well tolerated and even at the lowest dose level of aldoxorubicin (170 mg/m2); impressive tumor responses had been observed so far in seven patients with osteosarcoma. Tumor shrinkage was observed in three of seven patients following two treatment cycles.  One patient with advanced dedifferentiated chondrosarcoma (cartilage/bone cancer), chronic severe pain and inability to function normally demonstrated meaningful quality of life improvements, including stopping prescription narcotic pain medications and returning to full-time work. At that time, the trial was expected to be completed in the second half of 2015 [&lt;ulink linkID="1656187" linkType="Reference"&gt;1656187&lt;/ulink&gt;]. In June 2016,  further clinical data were presented at the 52nd ASCO meeting in Chicago, IL.  Complete response, partial response, stable disease, and progressive disease were reported in 0, 12.5, 75.0, and 12.5%; 0, 0, 50.0, and 50.0%; 0, 16.7, 83.3, and 0% of patients treated with aldoxorubicin 170, 250 or 350 mg/m2, respectively [&lt;ulink linkID="1767363" linkType="Reference"&gt;1767363&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, an open-label, single-center phase Ib trial (&lt;ulink linkID="94689" linkType="Protocol"&gt;NCT01706835&lt;/ulink&gt;; ALDOXORUBICIN-P1-PK-01) to assess the pharmacokinetics of aldoxorubicin in patients (expected n = 12) with metastatic solid tumors who have either relapsed or not responded to treatment with standard therapies was initiated in the US to assess the safety of infusion administration of aldoxorubicin at doses of 230 mg/m2 and 350 mg/m2 every 21 days for up to 8 consecutive cycles. At that time, the trial was expected to be completed in August 2013 [&lt;ulink linkID="1331631" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1331631" linkType="Reference"&gt;1331631&lt;/ulink&gt;],  [&lt;ulink linkID="1331799" linkType="Reference"&gt;1331799&lt;/ulink&gt;]. In May 2013, initial data from the trial were reported demonstrating a significant 250-fold lower distribution of aldoxorubicin to healthy tissues compared to doxorubicin. Data also showed that aldoxorubicin with a distribution half-life of 20 to 24 h following infusion was significantly longer than doxorubicin's initial half-life of 5 min. The drug showed prolonged clinical activity in two patients with  small cell lung cancer who had failed other therapies, including a partial tumor response at lower well-tolerated dose [&lt;ulink linkID="1425160" linkType="Reference"&gt;1425160&lt;/ulink&gt;]. By December 2013, the trial had been completed [&lt;ulink linkID="1508145" linkType="Reference"&gt;1508145&lt;/ulink&gt;].	In May 2014, further data were presented at the 50th ASCO meeting in Chicago, IL.    Aldoxorubicin possessed narrow volume of distribution and also, binds rapidly to albumin with slow clearance  from the circulation [&lt;ulink linkID="1570565" linkType="Reference"&gt;1570565&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2012, a single-center, dose-escalating phase Ib efficacy study of aldoxorubicin in combination with doxorubicin in patients (expected n = 24) with advanced solid tumors who have failed other therapies was initiated [&lt;ulink linkID="1310956" linkType="Reference"&gt;1310956&lt;/ulink&gt;]. In May 2013, the company reported that  doxorubicin was being administered at 50% of its MTD along with escalating doses of aldoxorubicin [&lt;ulink linkID="1424184" linkType="Reference"&gt;1424184&lt;/ulink&gt;]. In June 2013, data were presented from an open-label  trial (&lt;ulink linkID="90502" linkType="Protocol"&gt;NCT01673438&lt;/ulink&gt;) in ten patients at the 49th ASCO meeting in Chicago, IL.  In a patient, 30% tumor reduction following 4 cycles of aldoxorubicin was observed.   The combination of aldoxorubicin at 240 mg/m2 dose + 35 mg/m2 doxorubicin was  tolerated [&lt;ulink linkID="1425730" linkType="Reference"&gt;1425730&lt;/ulink&gt;], [&lt;ulink linkID="1432405" linkType="Reference"&gt;1432405&lt;/ulink&gt;]. In September 2013, similar   data were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands [&lt;ulink linkID="1481432" linkType="Reference"&gt;1481432&lt;/ulink&gt;] [&lt;ulink linkID="1482707" linkType="Reference"&gt;1482707&lt;/ulink&gt;]. By December 2013, the trial had been completed [&lt;ulink linkID="1508145" linkType="Reference"&gt;1508145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, an open-label, safety and dose-escalation, phase Ib study was initiated in patients (expected = 24) with advanced solid tumors who had failed standard therapies [&lt;ulink linkID="1177221" linkType="Reference"&gt;1177221&lt;/ulink&gt;]. In July 2011, phase Ib data from eight  patients treated with 165 and 260 mg/m2 doses of doxorubicin  equivalents demonstrated safety without DLTs.  At that time, dose escalation was ongoing [&lt;ulink linkID="1205814" linkType="Reference"&gt;1205814&lt;/ulink&gt;]. In August 2011, results from the phase Ib soft tissue sarcoma trial were expected in the   fourth quarter of 2011 and at that time, the trial was expected to be completed later that year [&lt;ulink linkID="1211374" linkType="Reference"&gt;1211374&lt;/ulink&gt;]. In July 2012, clinical data were presented from 41 patients with cancer enrolled in this trial at the 48th International Conference on Medicinal Chemistry, Poitiers, France. No significant adverse events were observed in 30 of the 41 patients who received up to a recommended 260 mg/m2 doxorubicin dose equivalent. At that time, seven patients had stable disease and five patients had a partial response, and three of the five patients with a partial response had not responded to prior therapy with doxorubicin [&lt;ulink linkID="1308199" linkType="Reference"&gt;1308199&lt;/ulink&gt;]. In September 2013, further   data were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands. The Cmax and AUC values of bound and free doxorubicin were dose-proportionally increased. Patients with small cell lung cancer and mesothelioma demonstrated tumor shrinkage [&lt;ulink linkID="1481433" linkType="Reference"&gt;1481433&lt;/ulink&gt;] [&lt;ulink linkID="1482707" linkType="Reference"&gt;1482707&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, interim clinical data on INNO-206 were presented at the 96th AACR meeting in Anaheim, CA. In an ongoing phase I study, cohorts of three to six patients with advanced cancer  were treated with an iv infusion of INNO-206 over 30 min once every 3 weeks at dose levels of 20, 40, 80, 135, 150, 180 and 200 mg/m2 doxorubicin equivalent. By that time, 28 patients had been treated with INNO-206. No DLT was observed under treatment with INNO-206 up to 180 mg/m2 doxorubicin equivalent. Somnolence  was observed at 200 mg/m2 in two of six patients but the causal relationship to the INNO-206 remained unclear. Disease stabilization was observed in eight patients for up to six cycles [&lt;ulink linkID="597178" linkType="Reference"&gt;597178&lt;/ulink&gt;].  In March 2006, data from the completed trial were presented at the Krebskongress meeting in Berlin, Germany. The drug was safe and effective at six-times the standard doxorubicin dose [&lt;ulink linkID="685569" linkType="Reference"&gt;685569&lt;/ulink&gt;]. Similar data were presented in August 2006 at the 19th International Medicinal Chemistry Symposium in Istanbul, Turkey [&lt;ulink linkID="687356" linkType="Reference"&gt;687356&lt;/ulink&gt;]. By November 2009, further results had shown that of 35 patients, 3 had partial tumor reductions and 20 had stable disease. The partial responses occurred in patients receiving the higher doses of INNO-206 [&lt;ulink linkID="1060096" linkType="Reference"&gt;1060096&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2004,  phase I clinical data were presented at the 40th ASCO meeting in New Orleans, LA.  Patients (n = 10) were administered INNO-206 as a 30-min iv infusion once every 3 weeks at one of three doses; either 27 mg/m2 (20 mg/m2 adriamycin equivalent), 54 mg/m2 (40 mg/m2 adriamycin equivalent) or 108 mg/m2 (80 mg/m2 adriamycin equivalent). The maximum tolerated dose was not established and one out of three evaluable patients had a minor response after two cycles at 27 mg/m2 [&lt;ulink linkID="544989" linkType="reference"&gt;544989&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2014, preclinical data were published. Data demonstrated that aldoxorubicin-treated mice showed significantly slower growth of the glioblastoma tumor  compared to vehicle-treated or doxorubicin-treated mice. In the study, five out of eight aldoxorubicin-treated mice were alive more than 60 days with a median survival of 62 days, whereas  the median survival of vehicle- and doxorubicin-treated mice was only 26 days. Aldoxorubicin also showed positive signs of accumulation and retention in tumor tissue [&lt;ulink linkID="1606630" linkType="Reference"&gt;1606630&lt;/ulink&gt;], [&lt;ulink linkID="1606533" linkType="Reference"&gt;1606533&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, preclinical data were presented at the 105th AACR meeting in San Diego, CA. In 6- to 8-week old athymic nude mice implanted with U87-luc cells, aldoxorubicin (480 microg/injection) induced tumor regression and significantly increased survival when compared with doxorubicin [&lt;ulink linkID="1538711" linkType="Reference"&gt;1538711&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2013, preclinical data had shown that the drug exhibited statistically significant efficacy and demonstrated the median survival of more than 63 days, compared with animals treated with doxorubicin or saline, which showed 25 days. Confirmation of the drug uptake to the tumor in brain suggested that the drug could shrink glioblastoma tumors  [&lt;ulink linkID="1515388" linkType="Reference"&gt;1515388&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2013, data were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands. In 6 to 8 week old female BALB/c (nu/nu) mice implanted with U87MG human glioma cells, treatment with aldoxorubicin showed near complete tumor regression and significantly increased survival when compared with control mice [&lt;ulink linkID="1481582" linkType="Reference"&gt;1481582&lt;/ulink&gt;]. Data also showed that, aldoxorubicin produced statistically significant improvement in survival rates in animals with a human model of glioblastoma when compared to doxorubicin. In March 2014, updated data were expected to be presented at the American Association of Cancer Research (AACR) meeting, San Diego, CA in April 2014 [&lt;ulink linkID="1531644" linkType="Reference"&gt;1531644&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, CyRx reported preclinical data from a confirmatory animal study showing that aldoxorubicin regressed  tumor growth in glioblastoma and increased the survival time compared with doxorubicin. Results of the study were scheduled to be presented in September 2013 at the European Society for Medical Oncology in Amsterdam, The Netherlands [&lt;ulink linkID="1450119" linkType="Reference"&gt;1450119&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2013, the company planned to initiate preclinical testing to evaluate the linker technology with a platinum-based chemotherapeutic agent and also to investigate a combination of the linker with lactosaminated albumin (LSA) [&lt;ulink linkID="1424184" linkType="Reference"&gt;1424184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2012, preclinical data from animal models of human tumors had demonstrated that the combination of aldoxorubicin and free doxorubicin administered at 50% each of their respective maximum tolerated dose provided complete and prolonged remissions in ovarian and pancreatic cancers with minimal weight loss compared with each drug administered individually at its MTD [&lt;ulink linkID="1310956" linkType="Reference"&gt;1310956&lt;/ulink&gt;]. In January 2013, similar data from an in vivo preclinical trial conducted in MIA PaCa-2 pancreatic xenograft models were published. Data demonstrated that iv treatment with aldoxorubicin resulted in complete and partial remissions up to the end of the experiment on day 43 compared to moderate tumor inhibition with unconjugated doxorubicin. The combination was well tolerated at all the low doses given when compared to aldoxorubicin alone. At that time, the data were expected to be presented at the ASCO meeting, in Chicago, IL, in May or June 2013 [&lt;ulink linkID="1363627" linkType="Reference"&gt;1363627&lt;/ulink&gt;], [&lt;ulink linkID="1363771" linkType="Reference"&gt;1363771&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data presented at the 103rd AACR meeting in Chicago, Illinois, showed that the drug induced complete tumor remissions in the laboratory [&lt;ulink linkID="1301102" linkType="Reference"&gt;1301102&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, interim data were reported from a preclinical study in which 50 mice had been implanted with multiple myeloma (MM) tumors. Tumor size significantly decreased in mice treated with INNO-206 compared with those in the control group, after three injections. There were substantially fewer deaths in the groups receiving INNO-206, than in the groups receiving doxorubicin. At that time, further preclinical studies in several MM models were planned [&lt;ulink linkID="1095662" linkType="Reference"&gt;1095662&lt;/ulink&gt;]. In December 2010,   the results were presented at the Annual Meeting and Exposition of the American Society of Hematology, Orlando, FL. In May 2012, data were published from the studies  in MM xenograft models, which compared INNO-206 to conventional doxorubicin and pegylated liposomal doxorubicin (PLD) alone, and in combination with &lt;ulink linkID="15954" linkType="Drug"&gt;bortezomib&lt;/ulink&gt; for anti-MM effect and toxicity. INNO-206 inhibited blood vessel formation and reduced MM cell growth in a pH-dependent manner. INNO-206 enhanced the anticancer effects of bortezomib. Studies  in mouse models demonstrated marked anti-MM effects at doses at which doxorubicin was extremely toxic. The combination of INNO-206 and bortezomib produced increased anti-MM effects compared to either agent alone [&lt;ulink linkID="1295333" linkType="Reference"&gt;1295333&lt;/ulink&gt;], [&lt;ulink linkID="1295436" linkType="Reference"&gt;1295436&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2009, data from a mouse model of SCLC were reported.  Mice with implanted H209 SCLC tumors received weekly 8 mg/kg iv injections of either doxorubicin or INNO-206, or 24 mg/kg of INNO-206. No anti-tumor activity was seen in either 8 mg/kg group; however, in the 24 mg/kg, tumor volumes increased by only 3.5-fold. The toxicity 24 mg/kg of INNO-206 was similar to that of 8 mg/kg of doxorubicin [&lt;ulink linkID="1033133" linkType="Reference"&gt;1033133&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2009, data were reported from a study assessing INNO-206 in an animal model of ovarian cancer. After being transplanted with A2780 ovarian tumor cells, 18 immunocompromized mice were randomized to receive two cycles of weekly intravenous injections of doxorubicin, INNO-206 or placebo. Tumor growth was monitored continuously for 12 days from the start of treatment. In INNO-206-treated mice there was a net two- to three-fold decrease in tumor volume, which was statistically significant (p &amp;lt; 0.05) compared with the doxorubicin group, in which there was a four- to five-fold increase in tumor volume, and the placebo group in which there was approximately a 20-fold increase in average volume [&lt;ulink linkID="1028965" linkType="Reference"&gt;1028965&lt;/ulink&gt;]. In April 2011, preclinical data combining INNO-206 with doxorubicin in an ovarian A2780 xenograft model were presented at the 102nd AACR meeting in Orlando, FL. The combination or INNO-206 alone produced complete remissions, whereas doxorubicin alone only demonstrated a  moderate effect and a body weight loss of -21%. The combination was better tolerated with a body weight loss of -12%; INNO-206 alone was -31% [&lt;ulink linkID="1175595" linkType="Reference"&gt;1175595&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, preclinical results from an animal model of pancreatic cancer were reported. A total of 30 mice lacking a normal immune system were implanted with human AsPC1 pancreatic cancer cells and were randomized to receive two cycles of weekly iv injections of doxorubicin, INNO-206 or placebo, administered 18 days after implantation. Compared with mice on placebo, those that received INNO-206 had a three-fold reduction in the average primary tumor size (p &amp;lt; 0.005). Doxorubicin-treated mice showed a 30% primary tumor reduction which was not statistically significant. Gemcitabine was also shown to give an approximate 30% reduction in primary tumor volume in a parallel experiment. No statistically significant inhibition of tumor spread occurred in either the INNO-206 or gemcitabine group. However, there was a substantial trend in the INNO-206 arm with an approximate  10-fold decrease in tumor spread to the liver and stomach. Toxicity was comparable in the two treatment groups, with mice in both showing an approximately 10% average weight loss compared with those on placebo, following two cycles [&lt;ulink linkID="1026915" linkType="Reference"&gt;1026915&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In July 2009, CytRx reported preclinical data on INNO-206 from an animal model of breast cancer. At the Tumor Biology Center in Freiburg, Germany, mice with compromised immune systems were implanted with human breast tumor cells and then treated with placebo, a maximum tolerated dose of doxorubicin, or a maximum tolerated dose of INNO-206. At 43 days post-implantation, an increase in tumor volume by an average of 2.7 fold was seen in the control group, a minor inhibition in tumor growth was seen in the doxorubicin arm, and a reduction by half was seen in the INNO-206 cohort. INNO-206 demonstrated improved efficacy compared with doxorubicin and showed comparable toxicity based on animal body-weight loss [&lt;ulink linkID="1025137" linkType="Reference"&gt;1025137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, preclinical data on INNO-206 were presented at the 19th AACR-NCI-EORTC International Conference in San Francisco, CA.  The standard MTD of doxorubicin (8 mg/kg bid) was compared to INNO-206 at 8 mg/kg bid or 24 mg/kg tid. INNO-206 showed greater efficacy in inhibiting tumor growth at the higher dose in breast carcinoma (M3366), ovarian carcinoma (A2780) and SCLC (H209) xenografts. Body weight changes were comparable between the two treatment groups [&lt;ulink linkID="842051" linkType="Reference"&gt;842051&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, preclinical data on INNO-206 were presented at the 96th AACR meeting in Anaheim, CA. Toxicity studies with INNO-206 in mice, rats or dogs did not identify any other notable adverse events when compared to doxorubicin's toxicity data. Preclinical tolerance for INNO-206 was  higher in mice, rats and dogs compared to the parent compound [&lt;ulink linkID="597315" linkType="Reference"&gt;597315&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2001, preclinical data were presented at the 92nd AACR meeting in New Orleans, LA. A murine renal cell carcinoma model showed that INNO-206 was superior to its parent compound [&lt;ulink linkID="545205" linkType="reference"&gt;545205&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2006, Innovive Pharmaceuticals  licensed INNO-206 from the Tumor Biology Center at the University of Freiburg [&lt;ulink linkID="685569" linkType="Reference"&gt;685569&lt;/ulink&gt;]. In September 2008, CytRx acquired Innovive [&lt;ulink linkID="945155" linkType="Reference"&gt;945155&lt;/ulink&gt;], [&lt;ulink linkID="945320" linkType="Reference"&gt;945320&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="307">Squamous cell carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2018-02-05T00:00:00.000Z</StatusDate><Source id="2002867" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="936">Kaposis sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1104834">NantCell Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="CL">Chile</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="936">Kaposis sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27164">Tumor Biology Center, Freiburg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-08-22T00:00:00.000Z</StatusDate><Source id="685569" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-07-28T00:00:00.000Z</StatusDate><Source id="1949073" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="936">Kaposis sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-10-29T00:00:00.000Z</StatusDate><Source id="1493506" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-10-31T00:00:00.000Z</StatusDate><Source id="1234968" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-23T00:00:00.000Z</StatusDate><Source id="1250696" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-23T00:00:00.000Z</StatusDate><Source id="1250696" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-09-22T00:00:00.000Z</StatusDate><Source id="945155" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-17T00:00:00.000Z</StatusDate><Source id="1177221" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-03-17T00:00:00.000Z</StatusDate><Source id="1501419" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="936">Kaposis sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-01-23T00:00:00.000Z</StatusDate><Source id="1518021" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-05-15T00:00:00.000Z</StatusDate><Source id="1290959" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-23T00:00:00.000Z</StatusDate><Source id="1250696" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-23T00:00:00.000Z</StatusDate><Source id="1250696" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1598380" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-30T00:00:00.000Z</StatusDate><Source id="1598380" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-27T00:00:00.000Z</StatusDate><Source id="1538363" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-27T00:00:00.000Z</StatusDate><Source id="1538363" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-27T00:00:00.000Z</StatusDate><Source id="1538363" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-27T00:00:00.000Z</StatusDate><Source id="1538363" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-24T00:00:00.000Z</StatusDate><Source id="1538268" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-27T00:00:00.000Z</StatusDate><Source id="1538363" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15585">CytRx Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-29T00:00:00.000Z</StatusDate><Source id="1597967" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27164">Tumor Biology Center, Freiburg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2004-06-18T00:00:00.000Z</StatusDate><Source id="544989" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1011256">Innovive Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-04-25T00:00:00.000Z</StatusDate><Source id="787196" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1011256">Innovive Pharmaceuticals Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2006-08-22T00:00:00.000Z</StatusDate><Source id="685569" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27164">Tumor Biology Center, Freiburg</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2001-03-24T00:00:00.000Z</StatusDate><Source id="545205" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="3">Breakthrough Therapy</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="US">US</Country><Indication id="2454">Glioblastoma</Indication><AwardedIndication>Glioblastoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="4">Planned</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-09T00:00:00.000Z</MileStoneDate><Source id="1450119" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="3378">Soft tissue sarcoma</Indication><AwardedIndication>Treatment of soft tissue sarcoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="US">US</Country><Indication id="1261">Small-cell lung cancer</Indication><AwardedIndication>Treatment of small cell lung cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-24T00:00:00.000Z</MileStoneDate><Source id="1597967" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="US">US</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-24T00:00:00.000Z</MileStoneDate><Source id="1597967" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="US">US</Country><Indication id="2454">Glioblastoma</Indication><AwardedIndication>Treatment of glioblastoma multiforme</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-09-24T00:00:00.000Z</MileStoneDate><Source id="1597967" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="3378">Soft tissue sarcoma</Indication><AwardedIndication>Treatment of soft tissue sarcoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-06-02T00:00:00.000Z</MileStoneDate><Source id="1527654" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="EU">EU</Country><Indication id="3378">Soft tissue sarcoma</Indication><AwardedIndication>Treatment of soft tissue sarcoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-03-26T00:00:00.000Z</MileStoneDate><Source id="1540970" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="US">US</Country><Indication id="3378">Soft tissue sarcoma</Indication><AwardedIndication>Treatment of soft tissue sarcoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-06-29T00:00:00.000Z</MileStoneDate><Source id="1205505" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="15585">CytRx Corp</OwnerCompany><Country id="US">US</Country><Indication id="1507">Pancreatic ductal adenocarcinoma</Indication><AwardedIndication>Treatment of adenocarcinoma of the pancreas.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-04-18T00:00:00.000Z</MileStoneDate><Source id="1189024" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01878"><Name>Topoisomerase II</Name><SwissprotNumbers><Swissprot>O16140</Swissprot><Swissprot>O24308</Swissprot><Swissprot>O61078</Swissprot><Swissprot>O93794</Swissprot><Swissprot>P06786</Swissprot><Swissprot>P08096</Swissprot><Swissprot>P12531</Swissprot><Swissprot>P15348</Swissprot><Swissprot>P27570</Swissprot><Swissprot>P30182</Swissprot><Swissprot>P30190</Swissprot><Swissprot>P34203</Swissprot><Swissprot>P41001</Swissprot><Swissprot>P87078</Swissprot><Swissprot>Q00942</Swissprot><Swissprot>Q01879</Swissprot><Swissprot>Q23670</Swissprot><Swissprot>Q5UQE6</Swissprot><Swissprot>Q9Y8G8</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2168177" linkType="reference" linkID="2168177"&gt;2168177&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1061183">Hercules Technology Management Co V Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1100315">PRA Health Sciences</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1103920">NantWorks LLC</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15585">CytRx Corp</Company><CountAsPrincipalActive>3</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>3</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>6</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="27164">Tumor Biology Center, Freiburg</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O</Smiles><Smiles>C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](Cc3c2c(c4c(c3O)C(=O)c5cccc(c5C4=O)OC)O)(/C(=N/NC(=O)CCCCCN6C(=O)C=CC6=O)/CO)O)N)O.Cl</Smiles></StructureSmiles><Deals><Deal id="109181" title="Innovive to develop the University of Freiburg's INNO-206 worldwide"></Deal><Deal id="132623" title="US Government to fund development of CytRx's oncology drug candidates "></Deal><Deal id="150465" title="KTB Tumorforschungs to license its patents to CytRx for the development and commercialization of aldoxorubicin worldwide   "></Deal><Deal id="158558" title="Hercules to loan CytRx to commercialize and manufacture aldoxorubicin against soft tissue sarcoma     "></Deal><Deal id="160078" title="PRA Health to conduct phase III for CytRx Corp's aldoxorubicin against soft tissue sarcoma "></Deal><Deal id="241496" title="NantCell to develop and commercialize CytRx's aldoxorubicin for various cancers worldwide       "></Deal></Deals><PatentFamilies><PatentFamily id="1605859" number="WO-00076551" title="Method for producing an injectable medicament preparation"></PatentFamily><PatentFamily id="1706050" number="WO-2011131314" title="Combination of drugs with protein-binding prodrugs"></PatentFamily><PatentFamily id="2007079" number="WO-2010102788" title="Prodrugs"></PatentFamily><PatentFamily id="2369900" number="WO-2009121564" title="Drug conjugates with polyglycerols"></PatentFamily><PatentFamily id="2581602" number="WO-2013124068" title="Combinations of albumin-based drug delivery systems"></PatentFamily><PatentFamily id="2756431" number="WO-2014093815" title="Anthracycline formulations"></PatentFamily><PatentFamily id="2839580" number="WO-2014197569" title="Cytotoxic agents for the treatment of cancer"></PatentFamily><PatentFamily id="4135637" number="WO-2018136659" title="Modulation of tumor cell susceptibility"></PatentFamily><PatentFamily id="4398127" number="WO-2019036485" title="haNK cetuximab combinations and methods"></PatentFamily><PatentFamily id="4429431" number="WO-2019050926" title="Aldoxorubicin combination treatments and methods"></PatentFamily><PatentFamily id="676266" number="WO-2012113571" title="Bisphosphonate-prodrugs"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="NantWorks LLC" id="1103920"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="CytRx Corp" id="15585"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Berlin Free University" id="20535"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Tumor Biology Center, Freiburg" id="27164"></CompanyLink><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>